Wegovy (semaglutide 2.4 mg) is a GLP-1 receptor agonist licensed by the MHRA for weight management, administered as a once-weekly injection
It is commonly used to manage constipation, support digestive health, and may help with cholesterol management as part of a balanced diet (NICE recognises psyllium's modest cholesterol-lowering effects when used regularly)
Being overweight and obese contributes to numerous health conditions, including cardiovascular disease, diabetes, sleep and musculoskeletal disorders, stroke, hormonal issues, certain cancers and a decreased lifespan
Efecto del semaglutide Beneficios sobre glucemia Semaglutide reduce la glucosa en sangre en ayunas y posprandial, con descensos del HbA1c de hasta 1,5-2% tras varios meses de terapia
Current state-level availability should be confirmed directly on the official website before initiating enrollment
The Long Term Effects of Semaglutide - A Two Year Study Lindsey Wood Feb 6, 2024 9 min read Behavioral strategies adjusting dietary habits and physical activity constitute the cornerstone of addressing overweight and obesity